Source: #Healthcare #Pharma #GLP1 #Obesity #HealthPolicy #Innovation GLP-1 drugs for obesity: Cost-effective, but coverage uncertain As reported by Axios International Vitals, the leading GLP-1 drugs from Novo Nordisk and Eli Lilly and Company are now becoming cost-effective for treating obesity, according to a new analysis from the Institute for Clinical and Economic Review (ICER): Why does this matter
3 January 2020
Physical and chemical stability of proteins The physical and chemical stability of protein drugs is another major challenge for their oral delivery
It may support: Reduction in visceral and subcutaneous fat Enhanced lipolysis during exercise Support for metabolic inflexibility or plateau states in fat loss programs 2
"Usually, the first line of treatment is to have a regular bedtime," said McGlinchey, since sleep terrors can often start with sleep deprivation
Hypothalamic dysfunction from paternally imprinted gene deletions is the main pathogenesis of PWS and is characterized by short stature, infantile hypotonia, hypothalamic hypogonadism, excessive appetite, and progressive obesity [1,2]
